Results 201 to 210 of about 84,983 (267)

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review. [PDF]

Hum Vaccin Immunother
Cohen JE, Mehmi I, Avner M, Moyers J, Hamid O.   +4 more
europepmc   +1 more source

Functional Repurposing of Magnetic Nanoparticle‐Assisted Hyperthermia for Immune Cell Labelling and Tracking

Small Methods, EarlyView.
We propose mild‐MHT protocol for the quick internalization of magnetic nanoparticles (MNPs) by immune cells. The heat induced by MNPs under alternating magnetic field stimulate MNPs diffusion and cell membrane invagination, accelerating the cellular internalization of MNPs. ABSTRACT Immune cell therapies show promise in hematologic malignancies and are
Giulia E. P. Nucci, Chiara Vitale, Alessandro di Girolamo, Niccolò Silvestri, Stefano Persano, Lorenci Gjurgjaj, Cristina Bottino, Roberta Castriconi, Teresa Pellegrino   +8 more
wiley   +1 more source

Why Is MS a More Frequent Complication of EBV Infection in Females? [PDF]

Immunol Rev
Dunn SE, Alvarez-Sanchez N, Steinman L.
europepmc   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Organ allocation and transplant equity in Brazil: the hidden burden of HLA homozygosity and hypersensitization. [PDF]

J Bras Nefrol
Santos Júnior ACSD, Nascimento E, Cruz ARD, Nascimento BV, Fabreti-Oliveira RA.   +4 more
europepmc   +1 more source

Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma

VIEW, EarlyView.
Cutaneous melanoma exhibits substantial molecular heterogeneity, and metabolic reprogramming may contribute to differences in tumor behavior and treatment response. In this study, we integrated multi‐omics data from SKCM cohorts to identify two metabolism‐associated subtypes with distinct oxidative stress profiles, immune microenvironments, prognostic ...
Qikun Gao, Ziyi Liu, Ying Xu
wiley   +1 more source

Solving another piece of the thrombotic thrombocytopenic purpura puzzle? [PDF]

Res Pract Thromb Haemost
Evangelidis P, Gavriilaki E.
europepmc   +1 more source

Plasma Proteomics Analysis Identifying IGFBP2 as a Potential Diagnostic Biomarker for Laryngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Currently, there are no blood biomarkers available for the early diagnosis of laryngeal squamous cell carcinoma (LSCC). The objective of this study was to search for potential plasma biomarkers for the diagnosis of LSCC. Methods Plasma samples were taken from patients with LSCC and healthy controls for proteomic analysis.
Shuang Teng, Ling‐Mei Qu, Jun‐Jie Liu, Yu‐Shan Li, Zi‐Qi Chen, Shuo Liu, Zhao‐Nan Xu, Meng Jin, Qiu‐Ying Li, Qin Wu, Hong‐Tian Yi, Xian‐Ji Shen, Bing‐Rui Yan, Ya‐Nan Sun   +13 more
wiley   +1 more source

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells. [PDF]

Front Immunol
Hamza H, Ghosh M, Rammensee HG, Planz O.
europepmc   +1 more source